Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 4/20 | 0.45 |
| ▸ | MME | P08473 | 10/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12974899 | 0.87 | MMEL1 (0.64) | MMEL1MME | |
| SCHEMBL12974944 | 0.87 | MMEL1 (0.56) | MMEL1MME | |
| SCHEMBL14959406 | 0.87 | MMEL1 (0.43) | MMEL1MME | |
| SCHEMBL12975716 | 0.87 | MMEL1 (0.43) | MMEL1MME | |
| SCHEMBL14952845 | 0.87 | MMEL1 (0.64) | MMEL1MME | |
| SCHEMBL16133215 | 0.87 | MMEL1 (0.60) | MMEL1MMECTSA | |
| SCHEMBL12974904 | 0.87 | CTSA (0.39) | MMEL1MMECETPNOS2CTSA | |
| SCHEMBL14873432 | 0.81 | MMEL1 (0.56) | MMEL1MMECTSA | |
| SCHEMBL12999389 | 0.77 | MMEL1 (0.53) | MMEL1MME | |
| SCHEMBL16133216 | 0.77 | MME (0.61) | MMEL1MMECTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | MMEL1 299/4885MME 1/4885CETP 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.